Capstone Partners  (IMAP USA) advised Pregistry — a global leader in safety studies during pregnancy — on its sale to CorEvitas, a portfolio company of Audax.

Founded in 2014, Pregistry leverages the expertise of over 75 pregnancy specialists covering a range of clinical, safety, regulatory, marketing, and technology needs to provide information that supports healthy pregnancies and births. Pregistry partners with global pharmaceutical and biotechnology companies to conduct observational studies on drug and vaccine safety during pregnancy. The company’s data informs individuals, providers, and industry stakeholders regarding health and safety during and after pregnancy, and ensures that prescribers, regulators, and pharmaceutical companies have the information needed to understand the potential benefits and risks of medications and vaccines during pregnancy.

CorEvitas’ acquisition of Pregistry accelerates the company’s continued expansion of syndicated registries, complementing its already deep base of expertise in conducting post-approval safety studies in autoimmune and inflammatory-mediated diseases. CorEvitas brings 20 years of experience creating and managing specialized patient registries to study real-world effectiveness and safety of advanced therapies.

CorEvitas is headquartered in Waltham, MA and is a portfolio company of Audax Private Equity. CorEvitas is a science-led, real-world data intelligence company. Using syndicated registry data and analytic services to understand the post-approval comparative effectiveness and safety of approved therapies, The company provides biopharmaceutical companies with objective data and clinical insights to demonstrate the value of their products to clinicians, patients, payers, and regulators.

Audax Group is a leading alternative investment manager with offices in Boston, New York, San Francisco and London. Since its founding in 1999, Audax has raised over $32 billion in capital across its Private Equity and Private Debt businesses.